Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Linzess Continues On Strong Launch Trajectory, Says Ironwood/Forest

This article was originally published in The Pink Sheet Daily

Executive Summary

Both Ironwood and its specialty pharma partner Forest Laboratories are tying their future to the gastrointestinal drug, which has been gaining traction during its first six months on the market, despite the tough environment for primary care drugs.

Advertisement

Related Content

Ironwood/Forest Hoping To Change The Conversation About Constipation
Ironwood/Forest Hoping To Change The Conversation About Constipation
Actavis’ Big Bet On A Diversified Hybrid Model
Actavis’ Big Bet On Diversified Hybrid Model Reflects Industry Trends
Ironwood’s Next Steps For Linzess: DTC and Traditional Lifecycle Management
IQWiG Backs Novartis’ Jetrea, Drops Almirall’s Constella On Same Day
Launching Linzess Into A Tough Primary Care Market
AstraZeneca And Ironwood Link Up To Bring Linaclotide To China

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS076005

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel